Latest Kaiser Health News Stories
Facing Headwinds on New Alzheimer’s Drug, Biogen Launches Controversial Campaign
The makers of Aduhelm, a drug approved last month despite concerns raised by experts about its effectiveness, have launched a website and ads designed to urge people who are worried about their memory to ask doctors about testing. But some health advocates say it is misleading because some memory loss with aging is normal.
KHN’s ‘What the Health?’: Here Comes Reconciliation
Democrats in Congress reached a tentative agreement to press ahead on a partisan bill that would dramatically expand health benefits for people on Medicare, those who buy their own insurance and individuals who have been shut out of coverage in states that didn’t expand Medicaid. Meanwhile, controversy continues to rage over whether vaccinated Americans will need a booster to protect against covid-19 variants, and who will pay for a new drug to treat Alzheimer’s disease. Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews KHN’s Rae Ellen Bichell, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about a mother and daughter who fought an enormous emergency room bill.
Why We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works
It could take years for follow-up studies to prove Aduhelm slows the disease — or doesn’t. Meanwhile, its maker will profit.
Doctores explican pros y contras de recetar la nueva droga para el Alzheimer
Mientras médicos y expertos en políticas de salud debaten los méritos de Aduhelm, el primer fármaco para el Alzheimer aprobado en 18 años, los pacientes simplemente quieren saber: “¿me ayudará?”.
Doctors Weigh Pros and Cons of Prescribing Hot-Button Alzheimer’s Drug
The potential benefits of Aduhelm are small, its effectiveness is not certain, and even the FDA Thursday shifted its guidance on who should get the drug. But physicians are dealing with an onslaught of interest from patients and their families, and figuring out which patients are best positioned to be helped by the drug will be difficult.
Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead?
Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.
KHN’s ‘What the Health?’: Un-Trumping the ACA
The Biden administration is moving to undo many of the changes the Trump administration made to the enrollment process for the Affordable Care Act to encourage more people to sign up for health insurance. Meanwhile, Congress is opening investigations into the controversial approval by the Food and Drug Administration of an expensive drug that might (or might not) slow the progression of Alzheimer’s disease. Joanne Kenen of Politico, Kimberly Leonard of Insider and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Marshall Allen of ProPublica about his new book, “Never Pay the First Bill: And Other Ways to Fight the Health Care System and Win.”
KHN’s ‘What the Health?’: The ACA Lives
In a surprisingly strong 7-2 decision, the Supreme Court turned back the latest constitutional challenge to the Affordable Care Act, likely heralding the end of GOP efforts to strike the law in its entirety through court action. Meanwhile, Democratic lawmakers are looking for ways to expand health benefits. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Andy Slavitt, who recently stepped down from the Biden administration’s covid response team, about his new book on the pandemic.
Journalists Discuss New Alzheimer’s Drug, Women’s Alcohol Use, the Hip-Hop and Opioids Link
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
KHN’s ‘What the Health?’: Our 200th Episode!
The federal approval of a controversial drug to treat Alzheimer’s disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast’s 200th episode, the panelists discuss what has surprised them most and least over the past four years.
FDA Weighs Approval of a Lucrative Alzheimer’s Drug, but Benefits Are Iffy
The agency is to decide by June 7 whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.
Trouble Managing Money May Be an Early Sign of Dementia
Long before they receive a dementia diagnosis, many people begin to mismanage their finances as their memory, organizational skills and self-control falter.
If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine?
Older patients with cancer, dementia or other serious illnesses should check with their doctors, but medical experts recommend the vaccine for most people.
Readers and Tweeters Fight Stigma and Salute Front-Line Workers
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Alzheimer’s Inc.: Colleagues Question Scientist’s Pricey Recipe Against Memory Loss
Dr. Dale Bredesen is a well-known, well-respected neurologist. But his colleagues think the comprehensive Alzheimer’s program he’s marketing through a private company is a mixture of free-for-the-asking common sense and unproven interventions.
U.S. Medical Panel Thinks Twice About Pushing Cognitive Screening For Dementia
Because seniors are at higher risk of cognitive impairment, proponents say screening asymptomatic older adults is an important strategy to identify people who may be developing dementia and to improve their care. But the U.S. Preventive Services Task Force cited insufficient evidence the tests are helpful.
Stalked By The Fear That Dementia Is Stalking You
For those worried they have an elevated risk of Alzheimer’s and other forms of dementia, testing is an option. But words to the wise: It’s hardly foolproof and could even backfire by heightening your fear of memory loss.
Finding Connections And Comfort At The Local Cafe
For Alzheimer’s patients and their caregivers, social and emotional isolation is a threat. But hundreds of “Memory Cafes” around the country offer them a chance to be with others who understand, and to receive social and cognitive stimulation in the process.
As His Wife’s Caregiver, A Doctor Discovers What’s Missing At Health Care’s Core
Harvard psychiatrist Arthur Kleinman shed his “veil of ignorance” during 11 years serving as the primary family caregiver for his wife, who had a rare form of early Alzheimer’s disease. In a new book, “The Soul of Care,” he offers suggestions for transforming health care ― just as caregiving transformed him.
La delicada tarea de quitarle el teléfono inteligente a un adulto mayor
Según el Centro de Investigación Pew, el 73% de los adultos mayores de 65 años usaron Internet en 2019, en comparación con el 43% en 2010.
